Business
Avalo Announces Participation in September Investor Conferences
WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief
About this update from Avalo Therapeutics, Inc.
[{"type":"text","content":"WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDates: September 9-11, 2024A pre-recorded presentation will be made available on Monday, September 9, 2024 at 7:00 AM ET. Stifel 2024 Virtual Immunology and Inflammation SummitFireside Chat Date: Tuesday, September 17, 2024Fireside Chat Time: 9:30 AM ET Webcasts of the pre-recorded presentation from the H.C. Wainwright Conference and the fireside chat from the Stifel Immunology and Inflammation Summit can be accessed under the “News/Events” page in the Investors section of the Company's website at www.avalotx.com. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com. About AVTX-009 AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in Hidradenitis Suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. Forward-Looking Statements This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s...